Monday, November 14, 2022
- 10:30AM-11:30AM
-
Abstract Number: 1670
Phase II Clinical Trial to Assess the Safety and Efficacy of Tocilizumab in Combination with Ipilimumab and Nivolumab for Treatment-naïve Metastatic Melanoma
Abstracts: Immunological Complications of Medical Therapy- 10:30AM-11:30AM
-
Abstract Number: 1667
Pre-existing Rheumatoid Arthritis Patients Initiating Immune Checkpoint Inhibitors for Cancer Treatment: A Comparative Cohort Study Investigating RA Flare and Mortality
Abstracts: Immunological Complications of Medical Therapy- 10:30AM-11:30AM
-
Abstract Number: 1673
Preconceptional NSAID Treatment Exposure Is Associated with a Significantly Longer Time-to-conception in Women with Spondyloarthritis: Analysis of the Prospective GR2 Cohort
Abstracts: Reproductive Issues in Rheumatic Disorders- 10:30AM-11:30AM
-
Abstract Number: 1668
Rheumatic Toxicities of Immune Checkpoint Inhibitors Predict Favourable Tumour Responses in Patients with Advanced Melanoma
Abstracts: Immunological Complications of Medical Therapy- 10:30AM-11:30AM
-
Abstract Number: 1672
The Impact of Systemic Sclerosis (SSc) on Women’s Health Evaluated with a New SSc-specific Patient-reported Questionnaire
Abstracts: Reproductive Issues in Rheumatic Disorders- 10:30AM-11:30AM
-
Abstract Number: 1665
The TLR7/8 Inhibitor Enpatoran Reverses Established Kidney Disease in the Interferon-Alpha-Accelerated NZB/W Mouse Model of Lupus
Abstracts: SLE – Animal Models- 10:30AM-11:30AM
-
Abstract Number: 1664
TRIM21 as a Regulator of UVB-Driven IFN Responses in Lupus
Abstracts: SLE – Animal Models- 11:30AM-1:00PM
-
Abstract Number: 1678
A Genome-Wide Association Analysis of 2,622,830 Individuals Reveals New Pathogenic Pathways in Gout
Plenary III- 11:30AM-1:00PM
-
Abstract Number: 1677
Chimeric Autoantigen-T Cell Receptor (CATCR)-T Cell Therapies to Selectively Target Autoreactive B Cells
Plenary III- 11:30AM-1:00PM
-
Abstract Number: 1675
Effectiveness of Intensive Diet and Exercise on Knee Pain Among Communities with Knee Osteoarthritis, Overweight, and Obesity: The WE-CAN Pragmatic Randomized Clinical Trial
Plenary III- 11:30AM-1:00PM
-
Abstract Number: 1680
Module Signatures of Synovial Single-cell States Identify Disease Phenotypes in Early Treatment-naive Rheumatoid Arthritis
Plenary III- 11:30AM-1:00PM
-
Abstract Number: 1676
Sarilumab in Patients with Relapsing Polymyalgia Rheumatica: A Phase 3, Multicenter, Randomized, Double Blind, Placebo Controlled Trial (SAPHYR)
Plenary III- 11:30AM-1:00PM
-
Abstract Number: 1679
The Childhood Arthritis and Rheumatology Research Alliance Start Time Optimization of Biologic Therapy in Polyarticular JIA (STOP-JIA) Study: Three-Year Outcomes
Plenary III- 1:00PM-3:00PM
-
Abstract Number: 1853
A Comparitive Study of NLRP3- and NLRP12-autoinflammatory Disease